Sonnet Bio Theraputics (SONN) is trading up 121.65% at $6.45 per share so far Friday. Sonnet stock is up sharp on no apparent news.
Sonnet Bio Theraputics (SONN) stock has fallen -65.58% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives SONN stock a score of 36 out of a possible 100.
That score is influenced by a long-term technical score of 3. SONN’s score also includes a short-term technical score of 17. The fundamental score for SONN is 87. In addition to the average rating from Wall Street analysts, SONN stock has a mean target price of 7. This means analysts expect the stock to increase 8.53% over the next 12 months.
What’s Happening with SONN Stock Today
Sonnet Bio Theraputics (SONN) stock has risen 121.65% while the S&P 500 is up 0.21% as of 9:43 AM on Friday, Jul 31. SONN is up $3.54 from the previous closing price of $2.91 on volume of 12,274,622 shares. Over the past year the S&P 500 is higher by 10.14% while SONN has fallen -65.58%. SONN lost -$57.44 per share in the over the last 12 months.